1. Scrip
  2. >>Business
  3. >>Deals

Telix Creates A Subsidiary Ahead Of New US Listing

 
• By Elizabeth Cairns

The new company, Rhine Pharma, hopes to avoid the isotope production issues that have dogged other radiopharmaceutical developers.

Two wire-frame glowing hands, handshake, technology, business, trust concept
• Source: Shutterstock

Last week, Australian radioligand developer Telix Pharmaceuticals revived its plans to list on the NASDAQ. But if this deal goes ahead, the company that lists in the US will be a different shape to the Telix which pulled its US IPO in a startling move this summer.

Key Takeaways
  • Telix Pharmaceuticals is to form a new company, Rhine Pharmaceuticals, which will develop an imaging compound and a therapeutic radioligand for prostate cancer.
  • The new company will be able to produce the isotopes for the products at the treatment facility, potentially swerving supply chain disruptions

That is because the group is hiving off Rhine Pharma, a unit working on therapies and tracers for prostate cancer technetium-99m and rhenium-188, isotopes it says can be more easily produced than

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Therapy Areas

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.